

**Table S1** Association between different variables and OS in NSCLC patients

Variable	Univariate			Multivariate		
	OS, median (years)	95% CI	P	P	HR	95% CI
OX40-tumors (20)						
Negative	2.553 (mean)	2.220–2.886	0.097*	0.025*	0.378	0.161–0.886
Positive	3.097 (mean)	2.203–3.992				
OX40-TILs (20)						
Negative	3.040	2.188–3.832	0.364			
Positive	1.720	0.428–3.052				
OX40L-tumors (20)						
Negative	3.040	2.317–3.763	0.027*	0.741		
Positive	1.080	0.301–1.859				
OX40L-TILs (20)						
Negative	3.230	2.884–3.576	0.221			
Positive	2.140	0.911–3.369				
PD-1-TILs (8)						
Negative	2.290	1.042–3.538	0.558			
Positive	2.970	1.358–4.582				
PD-L1-tumors (8)						
Negative	2.960	2.252–3.668	0.290			
Positive	1.290	0.621–1.959				
PD-L1- TILs (8)						
Negative	2.090	0.742–3.438	0.198			
Positive	3.090	2.524–3.656				
GAL-9-tumors (19)						
Negative	1.690	0.280–3.100	0.039*	0.041*	0.620	0.392–0.981
Positive	3.100	2.662–3.583				
GAL-9-TILs						
Negative	2.790	1.960–3.620	0.400			
Positive	1.080	0.000–2.278				
LAG-3-TILs (13)						
Negative	3.040	2.763–3.317	0.039*	0.005*	2.005	1.239–3.243
Positive	1.080	0.419–1.742				
MHC II-Tumor (15)						
Negative	2.090	0.827–3.353	0.083*	0.763		
Positive	3.030	2.660–3.400				
MHC II-TILs (15)						

Table S1 (continued)

Table S1 (continued)

Variable	Univariate			Multivariate		
	OS, median (years)	95% CI	P	P	HR	95% CI
Negative	1.390	0.629–2.151	0.014*	0.024*	0.585	0.367–0.932
Positive	3.230	2.617–3.843				
TIM-3-Tumors (25)						
Negative	2.790	1.970–3.610	0.615			
Positive	1.043	0.000–3.505				
TIM-3-TILs (25)						
Negative	2.960	2.268–3.652	0.034*	0.510		
Positive	1.080	0.228–1.932				
Age (years)						
<70	2.290	1.101–3.479	0.461			
≥70	2.980	1.851–4.109				
Gender						
Female	3.399(mean)	2.688–4.111	0.011*	0.068		
Male	2.404(mean)	2.064–2.745				
Smoking status						
Non-smoker	1.290	0.006–2.574	0.292			
Smoker	2.960	1.915–4.005				
Stage						
I–II	3.280	2.865–3.695	<0.001*	<0.001*	3.437	2.205–5.356
III–IV	0.730	0.486–0.974				
Pathology						
Non-AC	2.050	0.871–3.229	0.052*	0.156		
AC	3.230	2.520–3.735				
Grade						
G1	1.390	0.000–2.792	0.041*	0.364		
G2–3	2.980	0.390–2.215				
TILs percentage						
<30%	2.310	0.643–3.977	0.568			
≥30%	2.780	1.692–3.868				
Metastasis						
Negative	2.970	2.302–3.638	<0.001*	0.360		
Positive	0.670	0.000–1.620				

OX40, Tumor necrosis factor receptor superfamily member 4; OX40L, OX40 ligand; PD-1, program death-1; PD-L1, program death-ligand 1; GAL-9, Galectin-9; LAG-3, Lymphocyte-activation gene-3; MHC II, Major histocompatibility complex class II; TIM-3, T-cell immunoglobulin and mucin domain-3; TILs, tumor-infiltrating lymphocytes; AC, adenocarcinoma; OS, overall survival; 95% CI, 95% confidence interval; HR, hazard ratio. \*, Statistically significant P values.

**Table S2** Association between different variables and RFS in NSCLC patients

Variable	Univariate			Multivariate		
	RFS, median (years)	95% CI	P	P	HR	95% CI
OX40-tumors (20)						
Negative	2.316 (mean)	1.970–2.662	0.075	0.045	0.470	0.170–0.978
Positive	3.051 (mean)	2.139–3.971				
OX40-TILs (20)						
Negative	2.700	0.928–3.252	0.219			
Positive	1.410	1.062–1.778				
OX40L-tumors (20)						
Negative	1.910	0.979–2.841	0.066	0.829		
Positive	0.890	0.184–1.596				
OX40L-TILs (20)						
Negative	3.190	2.278–3.585	0.077	0.034	1.722	1.043–2.842
Positive	1.420	0.867–1.973				
PD-1-TILs (8)						
Negative	1.760	1.276–2.244	0.881			
Positive	1.470	0.584–2.356				
PD-L1-tumors (8)						
Negative	1.850	0.769–2.931	0.054	0.490		
Positive	0.970	0.769–1.231				
PD-L1- TILs (8)						
Negative	1.480	0.710–2.250	0.530			
Positive	1.760	0.039–3.481				
GAL-9-tumors (19)						
Negative	1.210	0.491–1.929	0.083	0.064		
Positive	2.720	1.402–4.038				
GAL-9-TILs						
Negative	1.800	0.832–2.768	0.036	0.023	2.358	1.127–4.933
Positive	0.670	0.086–1.254				
LAG-3-TILs (13)						
Negative	1.910	0.762–3.058	0.025	0.199		
Positive	0.870	0.267–1.473				
MHC II-Tumor (15)						
Negative	1.470	0.847–2.093	0.642			
Positive	1.910	0.545–3.275				
MHC II-TILs (15)						

Table S2 (continued)

Table S2 (continued)

Variable	Univariate			Multivariate		
	RFS, median (years)	95% CI	P	P	HR	95% CI
Negative	1.050	0.556–1.544	0.028	0.095		
Positive	2.980	1.638–4.332				
TIM-3-Tumors (25)						
Negative	1.760	1.246–2.274	0.622			
Positive	0.760	0.497–1.023				
TIM-3-TILs (25)						
Negative	1.800	1.230–2.370	0.048	0.768		
Positive	0.870	0.212–1.528				
Age (years)						
<70	1.510	0.916–2.104	0.313			
≥70	2.140	0.000–4.283				
Gender						
Female	3.210	2.304–3.765	0.084	0.551		
Male	1.470	0.950–1.990				
Smoking status						
Non-smoker	0.670	0.000–2.110	0.312			
Smoker	1.760	1.240–2.280				
Stage						
I-II	3.090	2.556–3.624	<0.001	<0.001	3.564	2.308–5.504
III-IV	0.660	0.494–0.862				
Pathology						
Non-AC	1.420	0.853–1.987	0.087	0.202		
AC	2.720	1.341–4.099				
Grade						
G1	1.080	0.802–1.358	0.049	0.374		
G2-3	1.820	0.612–3.028				
TILs percentage						
<30%	1.900	0.111–3.689	0.715			
≥30%	1.690	1.291–2.089				
Metastasis						
Negative	1.820	0.882–2.758	<0.001	0.274		
Positive	0.470	0.034–0.906				

OX40, Tumor necrosis factor receptor superfamily member 4; OX40L, OX40 ligand; PD-1, program death-1; PD-1, program death-1; PD-L1, program death-ligand 1; GAL-9, Galectin-9; LAG-3, Lymphocyte-activation gene-3; MHC II, Major histocompatibility complex class II; TIM-3, T-cell immunoglobulin and mucin domain-3; TILs, tumor-infiltrating lymphocytes; AC, adenocarcinoma; RFS, recurrence-free survival; 95% CI, 95% confidence interval; HR, hazard ratio. \*, Statistically significant P values.